Moreover, it suggests that AR-targeted vaccines could be integrated into existing therapeutic regimens, potentially enhancing overall treatment efficacy for prostate cancer patients in a metastatic setting, as well as after an early diagnosis. Here, AR is linked to Familial prostate cancer.